Page last updated: 2024-08-21

indazoles and Minimal Disease, Residual

indazoles has been researched along with Minimal Disease, Residual in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Artioli, G; Baumann, K; Bradley, WH; Calvert, PM; Dørum, A; Forget, F; Fuentes, J; González-Martín, A; Gupta, D; Hietanen, S; Kumar, A; Levy, T; Li, Y; Malinowska, IA; McCormick, C; Monk, BJ; Moore, RG; O'Cearbhaill, RE; O'Malley, DM; Pérez-Fidalgo, JA; Selle, F; Shahin, MS; Slomovitz, BM; Tusquets, I; Vulsteke, C	1

Trials

1 trial(s) available for indazoles and Minimal Disease, Residual

Article	Year
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecologic oncology, 2022, Volume: 166, Issue:1 Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Piperidines	2022

Article

Year

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.

Gynecologic oncology, 2022, Volume: 166, Issue:1

Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Piperidines

2022